Drugs / EU-Phesgo
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT07601620 Comparator | Jul 2026 → Apr 2027 expected | HER2 positive breast carcinoma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07495930 Comparator | Apr → Jul 2026 overdue | — | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EU-Phesgo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07601620 ↗ |
| Modality | Monoclonal antibody | “EU-Phesgo® is an original marketed drug product, with the generic name pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection)” NCT07601620 ↗ |